EGFR and lung cancer: Finally, it was observed that patients without methylation in SFRP1 have a longer PFS compared with patients with its methylation (9.7 months vs 2.0 months, p = 0.05), thus suggesting the intriguing hypothesis that activation of Wnt signaling by antagonist methylation could confer staminal properties linked to the EGFR TKIs resistance in lung cancer patients (48).